APLS PE Ratio & Valuation,Is APLS Overvalued

APLS Relative Valuation

APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLS is overvalued; if below, it's undervalued.

Historical Valuation

Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.84 is considered Undervalued compared with the five-year average of -26.20. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 45.72 to 53.49 according to relative valuation methord. Compared to the current price of 24.64 USD , Apellis Pharmaceuticals Inc is Undervalued By 46.11%.

Relative Value

Fair Zone

45.72-53.49

Current Price：24.64

46.11%

Undervalued

-16.51

-21.48

EV/EBITDA

Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBITDA of -21.48. The 5-year average EV/EBITDA is -19.55. The thresholds are as follows: Strongly Undervalued below -278.54, Undervalued between -278.54 and -149.05, Fairly Valued between 109.95 and -149.05, Overvalued between 109.95 and 239.45, and Strongly Overvalued above 239.45. The current Forward EV/EBITDA of -21.48 falls within the Historic Trend Line -Fairly Valued range.

-19.82

EV/EBIT

Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBIT of -19.82. The 5-year average EV/EBIT is -58.89. The thresholds are as follows: Strongly Undervalued below -798.11, Undervalued between -798.11 and -428.50, Fairly Valued between 310.71 and -428.50, Overvalued between 310.71 and 680.32, and Strongly Overvalued above 680.32. The current Forward EV/EBIT of -19.82 falls within the Historic Trend Line -Fairly Valued range.

3.84

Apellis Pharmaceuticals Inc. (APLS) has a current PS of 3.84. The 5-year average PS is 36.24. The thresholds are as follows: Strongly Undervalued below -71.32, Undervalued between -71.32 and -17.54, Fairly Valued between 90.03 and -17.54, Overvalued between 90.03 and 143.81, and Strongly Overvalued above 143.81. The current Forward PS of 3.84 falls within the Historic Trend Line -Fairly Valued range.

-98.04

P/OCF

Apellis Pharmaceuticals Inc. (APLS) has a current P/OCF of -98.04. The 5-year average P/OCF is -60.53. The thresholds are as follows: Strongly Undervalued below -350.81, Undervalued between -350.81 and -205.67, Fairly Valued between 84.62 and -205.67, Overvalued between 84.62 and 229.76, and Strongly Overvalued above 229.76. The current Forward P/OCF of -98.04 falls within the Historic Trend Line -Fairly Valued range.

164.71

P/FCF

Apellis Pharmaceuticals Inc. (APLS) has a current P/FCF of 164.71. The 5-year average P/FCF is -8.98. The thresholds are as follows: Strongly Undervalued below -133.94, Undervalued between -133.94 and -71.46, Fairly Valued between 53.50 and -71.46, Overvalued between 53.50 and 115.98, and Strongly Overvalued above 115.98. The current Forward P/FCF of 164.71 falls within the Strongly Overvalued range.

Apellis Pharmaceuticals Inc (APLS) has a current Price-to-Book (P/B) ratio of 7.96. Compared to its 3-year average P/B ratio of 20.79 , the current P/B ratio is approximately -61.73% higher. Relative to its 5-year average P/B ratio of 16.28, the current P/B ratio is about -51.14% higher. Apellis Pharmaceuticals Inc (APLS) has a Forward Free Cash Flow (FCF) yield of approximately 2.46%. Compared to its 3-year average FCF yield of -6.55%, the current FCF yield is approximately -137.62% lower. Relative to its 5-year average FCF yield of -7.16% , the current FCF yield is about -134.40% lower.

7.74

P/B

Median3y

20.79

Median5y

16.28

2.46

FCF Yield

Median3y

-6.55

Median5y

-7.16

Competitors Valuation Multiple

The average P/S ratio for APLS's competitors is , providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 132.98%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of APLS decreased by 23.03% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 196.83M to 458.58M.

The secondary factor is the P/E Change, contributed 105.14%to the performance.

Overall, the performance of APLS in the past 1 year is driven by Revenue Growth. Which is more sustainable.

132.98%

196.83M → 458.58M

Revenue Growth

-261.15%

-29.19 → 47.04

Margin Expansion

105.14%

33.42 → 68.56

P/E Change

-23.03%

31.91 → 24.56

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Apellis Pharmaceuticals Inc (APLS) currently overvalued or undervalued?

What is Apellis Pharmaceuticals Inc (APLS) fair value?

APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 45.72 to 53.49 according to relative valuation methord.

How does APLS's valuation metrics compare to the industry average?

What is the current P/B ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 16 2025?

As of Dec 16 2025, Apellis Pharmaceuticals Inc (APLS) has a P/B ratio of 7.96. This indicates that the market values APLS at 7.96 times its book value.

What is the current FCF Yield for Apellis Pharmaceuticals Inc (APLS) as of Dec 16 2025?

As of Dec 16 2025, Apellis Pharmaceuticals Inc (APLS) has a FCF Yield of 2.46%. This means that for every dollar of Apellis Pharmaceuticals Inc’s market capitalization, the company generates 2.46 cents in free cash flow.

What is the current Forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 16 2025?

As of Dec 16 2025, Apellis Pharmaceuticals Inc (APLS) has a Forward P/E ratio of -16.96. This means the market is willing to pay $-16.96 for every dollar of Apellis Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 16 2025?

As of Dec 16 2025, Apellis Pharmaceuticals Inc (APLS) has a Forward P/S ratio of 3.84. This means the market is valuing APLS at $3.84 for every dollar of expected revenue over the next 12 months.

APLS Valuation